S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
NASDAQ:ALZN

Alzamend Neuro News Headlines

$2.10
+0.06 (+2.94 %)
(As of 10/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.06
$2.10
50-Day Range
$2.26
$4.07
52-Week Range
$2.04
$33.55
Volume
1,082 shs
Average Volume
2.52 million shs
Market Capitalization
$182.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



Alzamend Neuro Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALZN
News Sentiment

-0.52

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALZN Articles
This Week

1

1

ALZN Articles
Average Week

Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.

Alzamend Neuro (NASDAQ:ALZN) News Headlines Today

SourceHeadline
MarketBeat logoShort Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Declines By 50.5%
americanbankingnews.com - October 14 at 2:12 AM
msn.com logoSee Why Alzamend Neuro Stock Is Rallying On Thursday
msn.com - September 30 at 4:40 PM
finance.yahoo.com logoWhy Alzamend Neuro Shares Are Surging Higher Today
finance.yahoo.com - September 30 at 4:40 PM
finance.yahoo.com logoAlzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
finance.yahoo.com - September 30 at 11:39 AM
reuters.com logoAlzamend Neuro Inc
reuters.com - September 24 at 11:14 AM
finance.yahoo.com logoCould The Alzamend Neuro, Inc. (NASDAQ:ALZN) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - September 15 at 7:13 AM
finance.yahoo.com logoAlzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
finance.yahoo.com - September 13 at 7:34 AM
nasdaq.com logoAlzamend Neuro Inc Shares Near 52-Week Low - Market Mover
nasdaq.com - August 28 at 4:18 AM
finance.yahoo.com logoAlzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
finance.yahoo.com - August 17 at 2:12 PM
finance.yahoo.com logoAlzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate
finance.yahoo.com - August 17 at 2:12 PM
finance.yahoo.com logoAlzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
finance.yahoo.com - August 4 at 9:37 AM
finance.yahoo.com logoAlzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
finance.yahoo.com - July 30 at 9:56 AM
finance.yahoo.com logoAlzamend Neuro Receives FDA "Study May Proceed" Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
finance.yahoo.com - July 28 at 8:09 PM
finance.yahoo.com logoHere's Why Alzamend Neuro Stock Is Shooting Higher Today
finance.yahoo.com - July 23 at 12:54 PM
finance.yahoo.com logoAlzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
finance.yahoo.com - July 23 at 7:54 AM
finance.yahoo.com logoAlzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
finance.yahoo.com - July 12 at 7:51 AM
finance.yahoo.com logoWhy Alzamend Neuro Stock Popped Today
finance.yahoo.com - June 28 at 6:34 PM
seekingalpha.com logoBiotech firm Alzamend Neuro's stock gives back 23% one day after 170% post-IPO gain
seekingalpha.com - June 18 at 3:55 PM
finance.yahoo.com logoAlzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
finance.yahoo.com - June 17 at 6:12 PM
nasdaq.com logoAlzamend Neuro, Inc. Common Stock (ALZN)
nasdaq.com - June 17 at 12:50 AM
benzinga.com logoAlzamend Neuro Shares Halted On Circuit Breaker
benzinga.com - June 16 at 7:50 PM
thestreet.com logoAlzamend Neuro Soars in First Trading Day
thestreet.com - June 16 at 7:50 PM
Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.